Conclusions & Recommendations
14.23.2 - Egypt
Conclusion/Recommendation:
TEC encourages the Ministry of Health to submit an application to treat additional districts in 2017 for consideration at TEC15 with evidence of MDA partner and funding.
Action:
Awaiting confirmation of funding.
TEC 14
2016
Eastern Mediterranean
Egypt
funding
14.24.1 - Pakistan
Conclusion/Recommendation:
TEC and ITI are very supportive of the Pakistan trachoma program and would like to contribute to its success. The Ministry of Health are encouraged to use the promised Zithromax® donation to leverage domestic financing and partner funding to support trachoma elimination.
Action:
The Ministry of Health have identified funding for MDAs in Chitral, KPK province and Shahdadkot, Sindh province. The national program will work with local health departments to schedule MDAs either in November-December 2016 or spring 2017, as local weather patterns allow.
TEC 14
2016
Eastern Mediterranean
Pakistan
funding
14.24.2 - Pakistan
Conclusion/Recommendation:
TEC approved the expansion of the Zithromax® donation to one additional district (FR Kala Dhaka in Mansehra) in 2017, contingent upon the identification of funding.
Action:
Funding awaited
TEC 14
2016
Eastern Mediterranean
Pakistan
funding
14.24.3 - Pakistan
Conclusion/Recommendation:
If funding can also be identified for the other requested areas, TEC welcomes a mid-year request for review at TEC15.
Action:
Funding awaited
TEC 14
2016
Eastern Mediterranean
Pakistan
funding
14.25.1 - Colombia
Conclusion/Recommendation:
TEC welcomes a mid-year request for review at TEC 15 for Caquetá.
Action:
Caqueta did not warrant treatment, but a separate new endemic district, Vichada, has been identified. Colombia will submit an application at TEC 16.
TEC 14
2016
Americas
Colombia
14.3.1 - Coverage Surveys
Conclusion/Recommendation:
Implementing partners are encouraged to consider conducting population-based coverage surveys where possible to determine, among other things, whether the request is being made against the actual population. If coverage is found to be low, programs are encouraged to identify explanatory factors, possible impact, and actions to be taken.
Action:
No action required
TEC 14
2016
coverage
14.4.1 - Zithromax® Following TT Surgeries
Conclusion/Recommendation:
TEC established a Working Group to gather evidence on:
- The benefit of administering Zithromax® post-operatively in both active programs and endgame settings (where there is very little ocular Chlamydia infection).
- How Zithromax® donated for use post-operatively in safely managed and accurately reported by the programs.
- Considerations of the extent of the donation commitment after MDA has stopped.
The Working Group is composed of:
Serge Resnikoff
David Addiss
Chad MacArthur
Amir Bedri
Paul Emerson/PJ Hooper
Action:
Potential solutions will be addressed in presentation at TEC 15.
TEC 14
2016
trichiasis, Zithromax® donation criteria
14.5.1 - Burundi
Conclusion/Recommendation:
TEC welcomes a request to be considered at TEC 15 once survey results are in and if warranted.
Action:
Survey data are not yet available. Survey are planned for early 2017 but are dependent on identifying funding
TEC 14
2016
Africa - East
Burundi
14.6.1 - Eritrea
Conclusion/Recommendation:
TEC encouraged Eritrea to submit a mid-year request for 2017 treatments once funding is identified.
Action:
A request will be reviewed at TEC 15
TEC 14
2016
Africa - East
Eritrea
funding
14.7.1 - Ethiopia - Amhara
Conclusion/Recommendation:
TEC recommended that the 2016 post-surgical approval move into Reserve (Special) category, since Zithromax® is not currently given following TT surgeries in this region and subject to confirmed need.
Action:
The allocation remains in Reserve (Special). Dr. Menbere will present on use of Zithromax® at surgery at TEC 15
TEC 14
2016
Africa - East
Ethiopia
Zithromax® donation criteria, trichiasis